Form 4: Akoya Biosciences COO Frederic Pla Reports Stock Transaction
SEC Form 4 Filing
Frederic Pla, Chief Operating Officer of Akoya Biosciences, reported a transaction involving the withholding of shares to cover taxes on a previously granted restricted stock unit award.
Summary
- On March 23, 2024, Frederic Pla, the Chief Operating Officer of Akoya Biosciences, Inc., had 2,006 shares of common stock withheld to cover taxes.
- This transaction was related to a restricted stock unit award granted on March 23, 2022, which vests in four equal annual installments starting March 23, 2023.
- Following the transaction, Pla directly owns 101,500 shares of Akoya Biosciences common stock.
- Pla also indirectly owns 20,000 shares through The Pla Family Trust dtd 8/7/14.
Sentiment
Score: 5
Explanation: This is a neutral reporting of a routine stock transaction related to executive compensation.
Industry Context
This is a routine filing related to executive compensation and is typical for publicly traded companies.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders as it relates to tax obligations on executive compensation.
Key Dates
| Date | Description |
|---|---|
| 08/07/2014 | Date of The Pla Family Trust |
| 03/23/2022 | Date of original restricted stock unit award grant |
| 03/23/2023 | First vesting date of the restricted stock unit award |
| 03/23/2024 | Date of stock withholding transaction |
| 03/25/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.